Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA 12.03.2024

About Gravity Analytica
Recent News
- 01.22.2025 - Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
- 01.13.2025 - J.P. Morgan Healthcare Conference
- 01.09.2025 - Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
Recent Filings
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 3,521 shares of Intellia’s common stock, with one-third of such RSUs vesting on
All equity vesting is subject to the employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
The above-described award was granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in
About
Intellia Contacts:
Investors:

Source: Intellia Therapeutics, Inc.